title: UTILISATION ANALYSIS OF ANTIHYPERTENSIVE DRUGS IN BOSNIA AND HERZEGOVINA FOR THE TIME-PERIOD 2013-2015.
abstract: OBJECTIVE
  Expenditures for drugs are increasingly burdening already insufficient funds for health protection. This is especially evident in less developed European countries such as Bosnia and Herzegovina. The question is whether such analyses can help save funds for financing treatment for diseases, with an emphasis on a more rational choice of drug for appropriate indication, whereby clinical complications of hypertension would be prevented and patients would have quality of their lives improved.
  
  
  OBJECTIVE
  Focus of research has been set on analysis of use of antihypertensive drugs in Bosnia and Herzegovina in the time-period January 2013-March 2015. Use of all drugs for treatment of hypertension in that time-period in the country has been shown in an unbiased manner.
  
  
  METHODS
  The study is designed as retrospective-prospective comparative research of use of antihypertensive drugs in BiH in a certain time-period. Data are collected from relevant drug utilisation database which has been established in Bosnia and Herzegovina since 2013.
  
  
  RESULTS
  We have calculated financial expenditure for prescribed antihypertensives in the time- period of 2013, 2014 and Q1 2015. Use of antihypertensives at the country level for this time-period is BAM 200,242,218. At the country level, physicians are most often opting for combination therapy: ACE inhibitors + diuretics (20.2%) and ACE inhibitors + Ca channel antagonists (18.0%).
  
  
  CONCLUSIONS
  In this research, it has been shown that modern drugs are used for treatment of hypertension in Bosnia and Herzegovina. These drugs are used in the same order as they are prescribed in developed countries.
authors.affiliation: Faculty of Medicine, University of Sarajevo, Sarajevo, Bosnia and Herzegovina.
authors.forename: Kenan
authors.initials: K
authors.lastname: Selmanovic
authors.affiliation: Institute of Pharmacology, Clinical Pharmacology and Toxicology, Faculty of Medicine, University of Sarajevo, Sarajevo, Bosnia and Herzegovina.
authors.forename: Svjetlana Loga
authors.initials: SL
authors.lastname: Zec
authors.affiliation: Department of Gastroenterology and Hepatology, Clinical Centre of Sarajevo University, Sarajevo, Bosnia and Herzegovina.
authors.forename: Nenad
authors.initials: N
authors.lastname: Vanis
authors.affiliation: Institute of Clinical Immunology, Clinical Center University of Sarajevo, Sarajevo, Bosnia and Herzegovina.
authors.forename: Lamija
authors.initials: L
authors.lastname: Zecevic
authors.affiliation: Faculty of Pharmacy, University of Sarajevo, Sarajevo, Bosnia and Herzegovina.
authors.forename: Manja
authors.initials: M
authors.lastname: Setkic
authors.affiliation: Institute of Oncology, Clinical Center University of Sarajevo, Sarajevo, Bosnia and Herzegovina.
authors.forename: Azra
authors.initials: A
authors.lastname: Rasic
authors.affiliation: Department of Gastroenterology, University Clinical Center Tuzla, Tuzla, Bosnia and Herzegovina.
authors.forename: Enver
authors.initials: E
authors.lastname: Zerem
keywords: antihypertensive drugs; hypertension; pharmacoeconomics; rational therapy